Suivant

Lecture automatique

The future of CTCL therapy

4 Vues • 08/09/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique